MiR-146a promotes remyelination in a cuprizone model of demyelinating injury

Jing Zhang1, Zheng Gang Zhang1, Mei Lu2

  • 1Department of Neurology, Henry Ford Health System, Detroit, MI 48202, United States.

Neuroscience
|February 27, 2017
PubMed

Insights

MicroRNAs, specifically miR-146a, show promise for treating demyelinating diseases. Enhancing miR-146a levels promotes oligodendrocyte differentiation and remyelination in the central nervous system.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Molecular Biology

Background:

  • Mature oligodendrocytes (OLs) are crucial for myelinating the central nervous system (CNS).
  • OL death causes demyelination and functional deficits, with limited effective therapies.
  • MicroRNAs (miRNAs) play a role in regulating OL function.

Purpose of the Study:

  • To investigate the potential of miR-146a in promoting oligodendrocyte progenitor cell (OPC) differentiation.
  • To determine if miR-146a enhances remyelination by targeting interleukin-1 receptor-associated kinase 1 (IRAK1).

Main Methods:

  • A cuprizone (CPZ)-induced demyelination mouse model was utilized.
  • miR-146a mimics or control mimics were infused into the corpus callosum.
  • Remyelination, OL differentiation, and IRAK1 levels were assessed using molecular and imaging techniques.

Main Results:

  • miR-146a mimic infusion significantly enhanced remyelination, evidenced by increased myelin basic proteins.
  • This was associated with an increase in newly generated mature OLs.
  • miR-146a treatment reduced IRAK1 protein levels and IRAK1-positive cells in the CNS.

Conclusions:

  • Exogenous miR-146a administration promotes OPC differentiation into mature OLs.
  • This mechanism enhances remyelination in demyelinated CNS tissue.
  • Targeting IRAK1 with miR-146a represents a potential therapeutic strategy for demyelinating diseases.

Related Concept Videos